RT Journal Article
SR Electronic
T1 Emergence of SARS-CoV-2 variants of concern in the pediatric population of the United States
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.22.21257660
DO 10.1101/2021.05.22.21257660
A1 Bard, Jennifer Dien
A1 Bootwalla, Moiz
A1 Leber, Amy
A1 Planet, Paul
A1 Moustafa, Ahmed M.
A1 Harris, Rebecca
A1 Chen, Pei Ying
A1 Shen, Lishuang
A1 Ostrow, Dejerianne
A1 Maglinte, Dennis
A1 Flores, Jessica
A1 Somak, Roy
A1 Ranganathan, Sarangarajan
A1 Perlman, Elizabeth
A1 Zheng, Xiaotian
A1 Selvarangan, Rangaraj
A1 Delaney, Meghan
A1 Campos, Joseph
A1 Michael, Drew G.
A1 Vilain, Eric
A1 LoTempio, Jonathan
A1 Dunn, James
A1 Jung, Sarah
A1 Dominguez, Samuel
A1 Judkins, Alexander R.
A1 Gai, Xiaowu
YR 2021
UL http://medrxiv.org/content/early/2021/05/24/2021.05.22.21257660.abstract
AB The evolution of SARS-CoV2 virus has led to the emergence of variants of concern (VOC). Children, particularly <12 years old not yet eligible for vaccines, continue to be important reservoirs of SARS-CoV-2 yet VOC prevalence data in this population is lacking. We report data from a genomic surveillance program that includes 9 U.S. children’s hospitals. Analysis of SARS-CoV-2 genomes from 2119 patients <19 years old between 03/20 to 04/21 identified 252 VOCs and 560 VOC signature mutations, most from 10/20 onwards. From 02/21 to 04/21, B.1.1.7 prevalence increased from 3.85% to 72.22% corresponding with the decline of B.1.429/B.1.427 from 51.82% to 16.67% at one institution. 71.74% of the VOC signature mutations detected were in children <12 years old, including 33 cases of B.1.1.7 and 119 of B.1.429/B.1.427. There continues to be a need for ongoing genomic surveillance, particularly among young children who will be the last groups to be vaccinated.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially funded by The Saban Research Institute at Children's Hospital Los Angeles intramural support for COVID-19 Directed ResearchAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the CHLA Institutional Review Board (CHLA-16-00429).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genomic data were uploaded to GISAID. The corresponding accessions are available upon request from the corresponding author.